AstraZeneca will partner with Schr?dinger to use the company's advanced computing platform to accelerate drug discovery efforts. Work conducted by AstraZeneca's medicinal and computational chemists will be used by Schr?dinger's computational platform to improve the design of compounds. In turn, this will identify potential new therapeutic candidates. Machine learning systematically analyses data to find connections with the artificial intelligence used to deduce previously unknown connections. Results are then used to gain a better understanding of the mechanisms of disease and the compounds that can treat them. https://www.biospace.com/article/astrazeneca-bolsters-machine-learning-use-for-drug-development-with-schrodinger-deal/